Midgard Science

ProJect Pharmaceutics

Martinsried, Germany project-pharmaceutics.com

From their website, Nov 2026

Work here? Claim this listing

About

ProJect Pharmaceutics GmbH develops formulations and manufacturing processes for injectable therapeutic products. It works with recombinant proteins, antibodies, ADCs, peptides, small molecules, viral vectors, liposomes, and nanoparticle systems for preclinical through commercial development. The company is based in Martinsried, Munich, Germany, with business development representation in Boston, MA.

Services

  • Formulation development

    Develops liquid and lyophilized injectable formulations for proteins, antibodies, peptides, ADCs, small molecules, and viral and nanoparticle systems.

    Assays & in vitro testing

  • Preformulation screening

    Screens physicochemical properties and formulation variables to identify stable and developable lead formulations.

    Assays & in vitro testing

  • High concentration & subcutaneous formulation

    Develops high-concentration formulations for subcutaneous delivery.

    Assays & in vitro testing

  • Lyophilization cycle development

    Develops freeze-drying cycles for client formulations and manufacturer equipment.

  • Downstream process development

    Develops purification and UF/DF steps around molecule stability and delivers drug substance in a usable formulation.

  • Analytical services & method development

    Runs and develops analytical methods for biologics, ADCs, cytotoxics, and viral therapeutics, including method implementation and optimization.

    Assays & in vitro testing

  • Forced degradation & stress studies

    Stresses lead formulations to identify degradation pathways and support formulation selection and method development.

    Assays & in vitro testing

  • In-use stability & clinical administration

    Simulates site preparation, dilution, holding, infusion, and injection to assess in-use stability and administration compatibility.

    Assays & in vitro testing

  • Technology transfer to fill & finish

    Develops formulations and fill-finish processes for transfer to a manufacturer’s filling line.

  • Non-GMP toxicology & stability batches

    Makes aseptic non-GMP preclinical batches of liquid or lyophilized product for toxicology, PK/PD, and stability studies.

    CDMO: development & manufacturing

Turnaround
Within 5 days reporting of analytical results · Within 5 days reporting of results after testing · 2 to 4 weeks from scope alignment to project start · 5 to 6 weeks of cycle development
What to send
Final formulation · Container · Fill volume · Information on your manufacturer’s dryer · Target product profile · Intended manufacturer, if known

Capabilities

Assays and studies
Lyophilization · ADCs · Toxicology · Process development · Antibodies · Fill-finish · Peptides · Small molecules · Bispecifics · Stability studies · SE-HPLC · AF4
11 moreDLS · nanoDSC · CG-MALS · cIEF · icIEF · IEX-HPLC · Electrophoresis · Light scattering · Calorimetry · Chromatography · Electron microscopy
Scale and capacity
Up to 1,000 vials per batch · ~1,000 2R vials per biologics batch · 2R to 100H vial sizes · Up to OEB5 cytotoxic containment
Therapeutic areas
Biologics · ADCs · Cytotoxics · Viral therapeutics · Live viral vaccines

Instruments and platforms

  • HOF pilot freeze-dryers
  • Wyatt Technology

Modalities and species

Modalities
Small molecule · Antibody · Bispecific · ADC · Peptide · Viral vector · Recombinant protein · Vaccine · LNP / formulation

Certifications

As the company states them, with the certificate or registry record where there is one.

  • GLPSelf-reported

    As listed: GLP-like documentation

  • GMPSelf-reported

Company

Type
CDMO
Founded
2010

Locations

Address
manufacturing 250+ short- and long-term stability runs completed 140 lyophili
Sites
Martinsried, Germany · Munich, Germany · Boston, MA, United States

Contacts

Similar labs

Work here? Claim this listing